Shopping Cart 0
Cart Subtotal
AED 0

Gastric Cancer - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 9175

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 18350

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 27525
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Gastric Cancer-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastric Cancer-Pipeline Review, H2 2018, provides an overview of the Gastric Cancer (Oncology) pipeline landscape.

Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. Risk factors include smoking, pernicious anemia, stomach polyps, infection with helicobacter pylori and family history of stomach cancer. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastric Cancer-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Gastric Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastric Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 3, 15, 85, 103, 12, 108, 18 and 7 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 11, 5, 1, 10 and 3 molecules, respectively.

Gastric Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Cancer (Oncology).

- The pipeline guide reviews pipeline therapeutics for Gastric Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Gastric Cancer (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Gastric Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Gastric Cancer (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Gastric Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 9

Gastric Cancer-Overview 10

Gastric Cancer-Therapeutics Development 11

Gastric Cancer-Therapeutics Assessment 50

Gastric Cancer-Companies Involved in Therapeutics Development 71

Gastric Cancer-Drug Profiles 153

Gastric Cancer-Dormant Projects 1398

Gastric Cancer-Discontinued Products 1409

Gastric Cancer-Product Development Milestones 1413

Appendix 1424


List Of Figure

List of Figures

Number of Products under Development for Gastric Cancer, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Top 10 Routes of Administration, H2 2018

Number of Products by Stage and Top 10 Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Gastric Cancer, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Gastric Cancer-Pipeline by 3SBio Inc, H2 2018

Gastric Cancer-Pipeline by AbbVie Inc, H2 2018

Gastric Cancer-Pipeline by AbGenomics International Inc, H2 2018

Gastric Cancer-Pipeline by Abion Inc, H2 2018

Gastric Cancer-Pipeline by Abpro, H2 2018

Gastric Cancer-Pipeline by Adaptimmune Therapeutics Plc, H2 2018

Gastric Cancer-Pipeline by ADC Therapeutics SA, H2 2018

Gastric Cancer-Pipeline by Advenchen Laboratories LLC, H2 2018

Gastric Cancer-Pipeline by Alkermes Plc, H2 2018

Gastric Cancer-Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H2 2018

Gastric Cancer-Pipeline by Alteogen Inc, H2 2018

Gastric Cancer-Pipeline by Ambrx Inc, H2 2018

Gastric Cancer-Pipeline by amcure GmbH, H2 2018

Gastric Cancer-Pipeline by Amgen Inc, H2 2018

Gastric Cancer-Pipeline by ANP Technologies Inc, H2 2018

Gastric Cancer-Pipeline by Antikor Biopharma Ltd, H2 2018

Gastric Cancer-Pipeline by Argenx SE, H2 2018

Gastric Cancer-Pipeline by Array BioPharma Inc, H2 2018

Gastric Cancer-Pipeline by Asana BioSciences LLC, H2 2018

Gastric Cancer-Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2018

Gastric Cancer-Pipeline by Astellas Pharma Inc, H2 2018

Gastric Cancer-Pipeline by AstraZeneca Plc, H2 2018

Gastric Cancer-Pipeline by Aurigene Discovery Technologies Ltd, H2 2018

Gastric Cancer-Pipeline by Avipep Pty Ltd, H2 2018

Gastric Cancer-Pipeline by Basilea Pharmaceutica Ltd, H2 2018

Gastric Cancer-Pipeline by Bayer AG, H2 2018

Gastric Cancer-Pipeline by BeiGene Ltd, H2 2018

Gastric Cancer-Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2018

Gastric Cancer-Pipeline by Betta Pharmaceuticals Co Ltd, H2 2018

Gastric Cancer-Pipeline by Biocon Ltd, H2 2018

Gastric Cancer-Pipeline by Bioleaders Corp, H2 2018

Gastric Cancer-Pipeline by BioLineRx Ltd, H2 2018

Gastric Cancer-Pipeline by Boehringer Ingelheim GmbH, H2 2018

Gastric Cancer-Pipeline by Bristol-Myers Squibb Co, H2 2018

Gastric Cancer-Pipeline by Camel-IDS NV, H2 2018

Gastric Cancer-Pipeline by Cancer Prevention Pharmaceuticals Inc, H2 2018

Gastric Cancer-Pipeline by CARsgen Therapeutics Ltd, H2 2018

Gastric Cancer-Pipeline by CBT Pharmaceuticals Inc, H2 2018

Gastric Cancer-Pipeline by Celgene Corp, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Gastric Cancer Therapeutic Products under Development, Key Players in Gastric Cancer Therapeutics, Gastric Cancer Pipeline Overview, Gastric Cancer Pipeline, Gastric Cancer Pipeline Assessment


Companies

3SBio Inc

AbbVie Inc

AbGenomics International Inc

Abion Inc

Abpro

Adaptimmune Therapeutics Plc

ADC Therapeutics SA

Advenchen Laboratories LLC

Alkermes Plc

Allist Shanghai Pharmaceutical Technology Co Ltd

Alteogen Inc

Ambrx Inc

amcure GmbH

Amgen Inc

ANP Technologies Inc

Antikor Biopharma Ltd

Argenx SE

Array BioPharma Inc

Asana BioSciences LLC

Aslan Pharmaceuticals Pte Ltd

Astellas Pharma Inc

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

Avipep Pty Ltd

Basilea Pharmaceutica Ltd

Bayer AG

BeiGene Ltd

Beijing Hanmi Pharmaceutical Co Ltd

Betta Pharmaceuticals Co Ltd

Biocon Ltd

Bioleaders Corp

BioLineRx Ltd

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Camel-IDS NV

Cancer Prevention Pharmaceuticals Inc

CARsgen Therapeutics Ltd

CBT Pharmaceuticals Inc

Celgene Corp

Celldex Therapeutics Inc

Cellestia Biotech AG

Celltrion Inc

Celon Pharma SA

Chipscreen Biosciences Ltd

CMG Pharmaceutical Co Ltd

Cristal Therapeutics BV

CSPC Pharmaceutical Group Limited

CytomX Therapeutics Inc

Cytori Therapeutics Inc

Daiichi Sankyo Co Ltd

Dr. Reddy's Laboratories Ltd

Eddingpharm Inc

Eisai Co Ltd

Eli Lilly and Co

EOS Biosciences Inc

Erytech Pharma SA

Esperance Pharmaceuticals Inc

Exelixis Inc

F-star Biotechnology Ltd

F. Hoffmann-La Roche Ltd

Fate Therapeutics Inc

Five Prime Therapeutics Inc

FLX Bio Inc

Frost Biologic Inc

Genelux Corp

Genentech Inc

GeneScience Pharmaceuticals Co Ltd

Genmab A/S

Gilead Sciences Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

Glycotope GmbH

Guangdong Zhongsheng Pharmaceutical Co Ltd

Halozyme Therapeutics Inc

Hanmi Pharmaceuticals Co Ltd

Harbin Gloria Pharmaceuticals Co Ltd

Horizon Pharma Plc

Hummingbird Bioscience Pte Ltd

Hutchison MediPharma Ltd

Ildong Pharmaceutical Co Ltd

Immunicum AB

Immunomedics Inc

Immunomet Therapeutics Inc

Immunomic Therapeutics Inc

Incyte Corp

InnoCare Pharma Ltd

Inovio Pharmaceuticals Inc

Inspyr Therapeutics Inc

Intezyne Inc

Ipsen SA

Jeil Pharmaceutical Co Ltd

JHL Biotech Inc

Jiangsu Hengrui Medicine Co Ltd

Jiangsu Kanion Pharmaceutical Co Ltd

Johnson & Johnson

Jounce Therapeutics Inc

JW Pharmaceutical Corp

Kazia Therapeutics Ltd

Konruns Pharmaceutical Co Ltd

Kringle Pharma Inc

Kyowa Hakko Kirin Co Ltd

LATITUDE Pharmaceuticals Inc

LegoChem Biosciences Inc

LinXis BV

Lycera Corp

MacroGenics Inc

MaxiVAX SA

MedImmune LLC

Merck & Co Inc

Merck KGaA

Merrimack Pharmaceuticals Inc

Mersana Therapeutics Inc

Merus NV

MetaMax Ltd

Millennium Pharmaceuticals Inc

Mitsubishi Tanabe Pharma Corp

Moderna Therapeutics Inc

Molecular Partners AG

Molecular Targeting Technologies Inc

Moleculin Biotech LLC

Mycenax Biotech Inc

NanoCarrier Co Ltd

Novartis AG

OBI Pharma Inc

Oncobiologics Inc

OncoMed Pharmaceuticals Inc

OncoResponse Inc

Ono Pharmaceutical Co Ltd

Opsona Therapeutics Ltd

Orano Med LLC

Patrys Ltd

Pfizer Inc

Pharma Mar SA

Pieris Pharmaceuticals Inc

Polaris Pharmaceuticals Inc

Prescient Therapeutics Ltd

Puma Biotechnology Inc

Rhizen Pharmaceuticals SA

Richter Gedeon Nyrt

Sanofi

Scancell Holdings Plc

Seattle Genetics Inc

Selecta Biosciences Inc

SELLAS Life Sciences Group Inc

Sequella Inc

Shanghai Henlius Biotech Co Ltd

Shionogi & Co Ltd

Sichuan Kelun Pharmaceutical Co Ltd

Simcere Pharmaceutical Group

Sino Biopharmaceutical Ltd

Sorrento Therapeutics Inc

Supratek Pharma Inc

SynCore Biotechnology Co Ltd

Synthon Holdings BV

Taiho Pharmaceutical Co Ltd

Takeda Pharmaceutical Co Ltd

Takis Srl

Tarveda Therapeutics Inc

Terns Pharmaceuticals Inc

Tessa Therapeutics Pte Ltd

Toray Industries Inc

Triumvira Immunologics Inc

Tyrogenex Inc (Inactive)

United BioPharma Inc

Unum Therapeutics Inc

Vaxon Biotech

Venus Remedies Ltd

Viracta Therapeutics Inc

Wuhan YZY Biopharma Co Ltd

Xencor Inc

XuanZhu Pharma Co Ltd

Zhejiang Jianfeng Group Company Ltd

Zymeworks Inc

Gastric Cancer-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastric Cancer-Pipeline Review, H2 2018, provides an overview of the Gastric Cancer (Oncology) pipeline landscape.

Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. Risk factors include smoking, pernicious anemia, stomach polyps, infection with helicobacter pylori and family history of stomach cancer. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastric Cancer-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Gastric Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastric Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 3, 15, 85, 103, 12, 108, 18 and 7 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 11, 5, 1, 10 and 3 molecules, respectively.

Gastric Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Cancer (Oncology).

- The pipeline guide reviews pipeline therapeutics for Gastric Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Gastric Cancer (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Gastric Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Gastric Cancer (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Gastric Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

Introduction 9

Gastric Cancer-Overview 10

Gastric Cancer-Therapeutics Development 11

Gastric Cancer-Therapeutics Assessment 50

Gastric Cancer-Companies Involved in Therapeutics Development 71

Gastric Cancer-Drug Profiles 153

Gastric Cancer-Dormant Projects 1398

Gastric Cancer-Discontinued Products 1409

Gastric Cancer-Product Development Milestones 1413

Appendix 1424


List Of Figure

List of Figures

Number of Products under Development for Gastric Cancer, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Top 10 Routes of Administration, H2 2018

Number of Products by Stage and Top 10 Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Gastric Cancer, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Gastric Cancer-Pipeline by 3SBio Inc, H2 2018

Gastric Cancer-Pipeline by AbbVie Inc, H2 2018

Gastric Cancer-Pipeline by AbGenomics International Inc, H2 2018

Gastric Cancer-Pipeline by Abion Inc, H2 2018

Gastric Cancer-Pipeline by Abpro, H2 2018

Gastric Cancer-Pipeline by Adaptimmune Therapeutics Plc, H2 2018

Gastric Cancer-Pipeline by ADC Therapeutics SA, H2 2018

Gastric Cancer-Pipeline by Advenchen Laboratories LLC, H2 2018

Gastric Cancer-Pipeline by Alkermes Plc, H2 2018

Gastric Cancer-Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H2 2018

Gastric Cancer-Pipeline by Alteogen Inc, H2 2018

Gastric Cancer-Pipeline by Ambrx Inc, H2 2018

Gastric Cancer-Pipeline by amcure GmbH, H2 2018

Gastric Cancer-Pipeline by Amgen Inc, H2 2018

Gastric Cancer-Pipeline by ANP Technologies Inc, H2 2018

Gastric Cancer-Pipeline by Antikor Biopharma Ltd, H2 2018

Gastric Cancer-Pipeline by Argenx SE, H2 2018

Gastric Cancer-Pipeline by Array BioPharma Inc, H2 2018

Gastric Cancer-Pipeline by Asana BioSciences LLC, H2 2018

Gastric Cancer-Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2018

Gastric Cancer-Pipeline by Astellas Pharma Inc, H2 2018

Gastric Cancer-Pipeline by AstraZeneca Plc, H2 2018

Gastric Cancer-Pipeline by Aurigene Discovery Technologies Ltd, H2 2018

Gastric Cancer-Pipeline by Avipep Pty Ltd, H2 2018

Gastric Cancer-Pipeline by Basilea Pharmaceutica Ltd, H2 2018

Gastric Cancer-Pipeline by Bayer AG, H2 2018

Gastric Cancer-Pipeline by BeiGene Ltd, H2 2018

Gastric Cancer-Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2018

Gastric Cancer-Pipeline by Betta Pharmaceuticals Co Ltd, H2 2018

Gastric Cancer-Pipeline by Biocon Ltd, H2 2018

Gastric Cancer-Pipeline by Bioleaders Corp, H2 2018

Gastric Cancer-Pipeline by BioLineRx Ltd, H2 2018

Gastric Cancer-Pipeline by Boehringer Ingelheim GmbH, H2 2018

Gastric Cancer-Pipeline by Bristol-Myers Squibb Co, H2 2018

Gastric Cancer-Pipeline by Camel-IDS NV, H2 2018

Gastric Cancer-Pipeline by Cancer Prevention Pharmaceuticals Inc, H2 2018

Gastric Cancer-Pipeline by CARsgen Therapeutics Ltd, H2 2018

Gastric Cancer-Pipeline by CBT Pharmaceuticals Inc, H2 2018

Gastric Cancer-Pipeline by Celgene Corp, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Gastric Cancer Therapeutic Products under Development, Key Players in Gastric Cancer Therapeutics, Gastric Cancer Pipeline Overview, Gastric Cancer Pipeline, Gastric Cancer Pipeline Assessment


Companies

3SBio Inc

AbbVie Inc

AbGenomics International Inc

Abion Inc

Abpro

Adaptimmune Therapeutics Plc

ADC Therapeutics SA

Advenchen Laboratories LLC

Alkermes Plc

Allist Shanghai Pharmaceutical Technology Co Ltd

Alteogen Inc

Ambrx Inc

amcure GmbH

Amgen Inc

ANP Technologies Inc

Antikor Biopharma Ltd

Argenx SE

Array BioPharma Inc

Asana BioSciences LLC

Aslan Pharmaceuticals Pte Ltd

Astellas Pharma Inc

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

Avipep Pty Ltd

Basilea Pharmaceutica Ltd

Bayer AG

BeiGene Ltd

Beijing Hanmi Pharmaceutical Co Ltd

Betta Pharmaceuticals Co Ltd

Biocon Ltd

Bioleaders Corp

BioLineRx Ltd

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Camel-IDS NV

Cancer Prevention Pharmaceuticals Inc

CARsgen Therapeutics Ltd

CBT Pharmaceuticals Inc

Celgene Corp

Celldex Therapeutics Inc

Cellestia Biotech AG

Celltrion Inc

Celon Pharma SA

Chipscreen Biosciences Ltd

CMG Pharmaceutical Co Ltd

Cristal Therapeutics BV

CSPC Pharmaceutical Group Limited

CytomX Therapeutics Inc

Cytori Therapeutics Inc

Daiichi Sankyo Co Ltd

Dr. Reddy's Laboratories Ltd

Eddingpharm Inc

Eisai Co Ltd

Eli Lilly and Co

EOS Biosciences Inc

Erytech Pharma SA

Esperance Pharmaceuticals Inc

Exelixis Inc

F-star Biotechnology Ltd

F. Hoffmann-La Roche Ltd

Fate Therapeutics Inc

Five Prime Therapeutics Inc

FLX Bio Inc

Frost Biologic Inc

Genelux Corp

Genentech Inc

GeneScience Pharmaceuticals Co Ltd

Genmab A/S

Gilead Sciences Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

Glycotope GmbH

Guangdong Zhongsheng Pharmaceutical Co Ltd

Halozyme Therapeutics Inc

Hanmi Pharmaceuticals Co Ltd

Harbin Gloria Pharmaceuticals Co Ltd

Horizon Pharma Plc

Hummingbird Bioscience Pte Ltd

Hutchison MediPharma Ltd

Ildong Pharmaceutical Co Ltd

Immunicum AB

Immunomedics Inc

Immunomet Therapeutics Inc

Immunomic Therapeutics Inc

Incyte Corp

InnoCare Pharma Ltd

Inovio Pharmaceuticals Inc

Inspyr Therapeutics Inc

Intezyne Inc

Ipsen SA

Jeil Pharmaceutical Co Ltd

JHL Biotech Inc

Jiangsu Hengrui Medicine Co Ltd

Jiangsu Kanion Pharmaceutical Co Ltd

Johnson & Johnson

Jounce Therapeutics Inc

JW Pharmaceutical Corp

Kazia Therapeutics Ltd

Konruns Pharmaceutical Co Ltd

Kringle Pharma Inc

Kyowa Hakko Kirin Co Ltd

LATITUDE Pharmaceuticals Inc

LegoChem Biosciences Inc

LinXis BV

Lycera Corp

MacroGenics Inc

MaxiVAX SA

MedImmune LLC

Merck & Co Inc

Merck KGaA

Merrimack Pharmaceuticals Inc

Mersana Therapeutics Inc

Merus NV

MetaMax Ltd

Millennium Pharmaceuticals Inc

Mitsubishi Tanabe Pharma Corp

Moderna Therapeutics Inc

Molecular Partners AG

Molecular Targeting Technologies Inc

Moleculin Biotech LLC

Mycenax Biotech Inc

NanoCarrier Co Ltd

Novartis AG

OBI Pharma Inc

Oncobiologics Inc

OncoMed Pharmaceuticals Inc

OncoResponse Inc

Ono Pharmaceutical Co Ltd

Opsona Therapeutics Ltd

Orano Med LLC

Patrys Ltd

Pfizer Inc

Pharma Mar SA

Pieris Pharmaceuticals Inc

Polaris Pharmaceuticals Inc

Prescient Therapeutics Ltd

Puma Biotechnology Inc

Rhizen Pharmaceuticals SA

Richter Gedeon Nyrt

Sanofi

Scancell Holdings Plc

Seattle Genetics Inc

Selecta Biosciences Inc

SELLAS Life Sciences Group Inc

Sequella Inc

Shanghai Henlius Biotech Co Ltd

Shionogi & Co Ltd

Sichuan Kelun Pharmaceutical Co Ltd

Simcere Pharmaceutical Group

Sino Biopharmaceutical Ltd

Sorrento Therapeutics Inc

Supratek Pharma Inc

SynCore Biotechnology Co Ltd

Synthon Holdings BV

Taiho Pharmaceutical Co Ltd

Takeda Pharmaceutical Co Ltd

Takis Srl

Tarveda Therapeutics Inc

Terns Pharmaceuticals Inc

Tessa Therapeutics Pte Ltd

Toray Industries Inc

Triumvira Immunologics Inc

Tyrogenex Inc (Inactive)

United BioPharma Inc

Unum Therapeutics Inc

Vaxon Biotech

Venus Remedies Ltd

Viracta Therapeutics Inc

Wuhan YZY Biopharma Co Ltd

Xencor Inc

XuanZhu Pharma Co Ltd

Zhejiang Jianfeng Group Company Ltd

Zymeworks Inc